Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Your Article Summary
See Latest ArticlesA 6-Month, Multicenter, Single-Arm Pilot Study to Evaluate the Efficacy and Safety of Generic Tacrolimus (TacroBell) After Primary Renal Transplantation
Transplantation Proceedings, 07/02/09
Kim SJ et al. - Tacrolimus has been shown to be an important immunosuppressive agent in organ and bone marrow transplantation. Treatment with TacroBell is considered to be efficient and safe after primary renal transplantation.
Related Articles
Association between exposure to topical tacrolimus or pimecrolimus and cancers
Annals of Pharmacotherapy, 11/16/09
Relevance Score: 92%
A prospective randomized open study in liver transplant recipients: Daclizumab, mycophenolate mofetil, and tacrolimus versus tacrolimus and steroids
Liver Transplantation, 11/03/09
Relevance Score: 89%
Prediction of DAS28-CRP remission in patients with rheumatoid arthritis treated with tacrolimus at 6 months by baseline variables
Modern Rheumatology, 10/05/09
Relevance Score: 89%
Relationship between tacrolimus blood concentrations and clinical outcome during the first 4 weeks after SCT in children
Bone Marrow Transplantation, 11/19/09
Relevance Score: 88%
Population Pharmacokinetics and Pharmacogenetics of Tacrolimus in De Novo Pediatric Kidney Transplant Recipients
Clinical Pharmacology & Therapeutics, 10/29/09
Relevance Score: 87%
Today in Transplantation...keeping you current
Receive free subspecialty "5-minute updates" via email
Sotrastaurin, a Novel Small Molecule Inhibiting Protein Kinase C: First Clinical Results in Renal-Transplant Recipients
American Journal of Transplantation, 02/09/10
Randomized Controlled Trial: Lisinopril Reduces Proteinuria, Ammonia, and Renal Polypeptide Tubular Catabolism in Patients With Chronic Allograft Nephropathy
Transplantation, 02/09/10
Switch to a Sirolimus-Based Immunosuppression in Long-Term Renal Transplant Recipients: Reduced Rate of Malignancies and Nonmelanoma Skin Cancer in a Prospective, Randomized, Assessor-Blinded, Controlled Clinical Trial
American Journal of Transplantation, 02/09/10
Article Search
Sponsor